U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908979) titled 'Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer' on Oct. 19.
Brief Summary: RETAIN-3 is a phase II study in patients with cT2-T3N0M0 muscle-invasive urothelial carcinoma of the bladder. Participants will receive neoadjuvant enfortumab vedotin and pembrolizumab followed by clinical and biomarker-based assessment to inform subsequent treatment management.
Study Start Date: Oct. 16
Study Type: INTERVENTIONAL
Condition:
Bladder Cancer
Urothelial Carcinoma
Muscle-Invasive Bladder Carcinoma
Muscle-invasive Bladder Urothelial Carcinoma
Intervention:
DRUG: Enfortumab vedotin
1.25 mg/kg (maximum 125 mg) intravenously...